110 related articles for article (PubMed ID: 30656994)
1. Impact of unfavorable factors on outcomes among inoperable stage II-IV Nonsmall cell lung cancer patients treated with proton therapy.
Zhu HJ; Nichols RC; Henderson RH; Morris CG; Flampouri S; Pham DC; Klassen CL; Seeram V; Cury JD; Jones L; McGee L; Hoppe BS
Acta Oncol; 2019 Mar; 58(3):313-319. PubMed ID: 30656994
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer.
Gomez DR; Gillin M; Liao Z; Wei C; Lin SH; Swanick C; Alvarado T; Komaki R; Cox JD; Chang JY
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):665-70. PubMed ID: 23688815
[TBL] [Abstract][Full Text] [Related]
3. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
Cicenas S; Zaliene A; Atkocius V
Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
[TBL] [Abstract][Full Text] [Related]
4. Results of high-dose thoracic irradiation incorporating beam's eye view display in non-small cell lung cancer: a retrospective multivariate analysis.
Hazuka MB; Turrisi AT; Lutz ST; Martel MK; Ten Haken RK; Strawderman M; Borema PL; Lichter AS
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):273-84. PubMed ID: 8407401
[TBL] [Abstract][Full Text] [Related]
5. High-dose proton beam therapy for stage I non-small cell lung cancer: Clinical outcomes and prognostic factors.
Makita C; Nakamura T; Takada A; Takayama K; Suzuki M; Azami Y; Kato T; Tsukiyama I; Hareyama M; Kikuchi Y; Daimon T; Hata M; Inoue T; Fuwa N
Acta Oncol; 2015 Mar; 54(3):307-14. PubMed ID: 25291076
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Petty WJ; Urbanic JJ; Ahmed T; Hughes R; Levine B; Rusthoven K; Papagikos M; Ruiz JR; Lally BE; Chan M; Clark H; D'Agostino RB; Blackstock AW
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):527-535. PubMed ID: 30003996
[TBL] [Abstract][Full Text] [Related]
7. Daily Step Counts: A New Prognostic Factor in Locally Advanced Non-Small Cell Lung Cancer?
Ohri N; Halmos B; Bodner WR; Cheng H; Guha C; Kalnicki S; Garg M
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):745-751. PubMed ID: 31398385
[TBL] [Abstract][Full Text] [Related]
8. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center.
Bush DA; Cheek G; Zaheer S; Wallen J; Mirshahidi H; Katerelos A; Grove R; Slater JD
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):964-8. PubMed ID: 23845845
[TBL] [Abstract][Full Text] [Related]
9. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
10. Proton Beam Therapy for Histologically or Clinically Diagnosed Stage I Non-Small Cell Lung Cancer (NSCLC): The First Nationwide Retrospective Study in Japan.
Ohnishi K; Nakamura N; Harada H; Tokumaru S; Wada H; Arimura T; Iwata H; Sato Y; Sekino Y; Tamamura H; Mizoe JE; Ogino T; Ishikawa H; Kikuchi Y; Okimoto T; Murayama S; Akimoto T; Sakurai H
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):82-89. PubMed ID: 31580927
[TBL] [Abstract][Full Text] [Related]
11. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
[TBL] [Abstract][Full Text] [Related]
14. The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.
Wang L; Correa CR; Zhao L; Hayman J; Kalemkerian GP; Lyons S; Cease K; Brenner D; Kong FM
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1383-90. PubMed ID: 18929449
[TBL] [Abstract][Full Text] [Related]
15. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
[TBL] [Abstract][Full Text] [Related]
16. Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas : Ablative dose PBT for NSCLC.
Lee SU; Moon SH; Cho KH; Pyo HR; Kim JY; Kim DY; Kim TH; Suh YG; Kim YJ
Strahlenther Onkol; 2016 Sep; 192(9):649-57. PubMed ID: 27282279
[TBL] [Abstract][Full Text] [Related]
17. Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC).
Rieber J; Deeg A; Ullrich E; Foerster R; Bischof M; Warth A; Schnabel PA; Muley T; Kappes J; Heussel CP; Welzel T; Thomas M; Steins M; Dienemann H; Debus J; Hoffmann H; Rieken S
Lung Cancer; 2016 Jan; 91():41-7. PubMed ID: 26711933
[TBL] [Abstract][Full Text] [Related]
18. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
[TBL] [Abstract][Full Text] [Related]
19. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer.
Nakajima K; Iwata H; Ogino H; Hattori Y; Hashimoto S; Toshito T; Hayashi K; Akita K; Baba F; Nakamae K; Mizoe JE; Shibamoto Y
Radiat Oncol; 2018 Oct; 13(1):199. PubMed ID: 30305125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
